MCID: HYP063
MIFTS: 51

Hypersplenism

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Hypersplenism

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism 12 55 44 15 17 72 33
Hypersplenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6376
ICD9CM 35 289.4
MeSH 44 D006971
NCIt 50 C34714
SNOMED-CT 68 58381000
ICD10 33 D73.1
UMLS 72 C0020532

Summaries for Hypersplenism

MalaCards based summary : Hypersplenism, also known as hypersplenia, is related to portal hypertension and esophageal varix. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 75 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Hypersplenism

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 portal hypertension 31.5 THPO F2 ALB
2 esophageal varix 31.1 SERPINC1 F2 ALB
3 liver cirrhosis 30.9 THPO SERPINC1 F2 ALB
4 deficiency anemia 30.8 THPO EPO ALB
5 hepatic coma 30.8 F2 ALB
6 schistosomiasis 30.8 IFNG F2 ALB
7 portal vein thrombosis 30.7 SERPINC1 F2
8 abdominal tuberculosis 30.6 F2 ALB
9 purpura 30.5 THPO SERPINC1 F2
10 hepatorenal syndrome 30.4 F2 ALB
11 hepatitis b 30.3 IFNG F2 ALB
12 pancytopenia 30.3 THPO EPO CSF2
13 endocarditis 30.3 SERPINC1 F2 ALB
14 peripheral vascular disease 30.0 SERPINC1 F2 ALB
15 visceral leishmaniasis 30.0 IFNG FOXP3 ALB
16 myelofibrosis 29.8 THPO EPO BMP6
17 splenic disease 29.5 THPO F2 EPO ALB
18 vascular disease 29.2 SERPINC1 F2 BMP6 ALB
19 acquired immunodeficiency syndrome 28.7 IFNG EPO CSF2 CD4 ALB
20 thrombocytosis 28.5 THPO SERPINC1 F2 EPO CSF2
21 aplastic anemia 27.9 THPO IFNG FOXP3 EPO CSF2 ALB
22 malaria 27.8 SERPINC1 IFNG FOXP3 EPO CSF2 ALB
23 splenomegaly 11.7
24 nodular regenerative hyperplasia 11.2
25 thrombocytopenia 10.8
26 non-a-e hepatitis 10.7 F2 ALB
27 antipyrine metabolism 10.7 F2 ALB
28 epstein-barr virus hepatitis 10.7 F2 ALB
29 hepatic tuberculosis 10.6 F2 ALB
30 kwashiorkor 10.6 F2 ALB
31 infantile liver failure syndrome 1 10.6 F2 ALB
32 calciphylaxis 10.6 EPO ALB
33 ascending cholangitis 10.6 F2 ALB
34 varicose veins 10.6
35 fetal erythroblastosis 10.5 EPO ALB
36 miliary tuberculosis 10.5 IFNG EPO
37 pure red-cell aplasia 10.5 EPO ALB
38 compartment syndrome 10.5 F2 ALB
39 tuberculous peritonitis 10.5 IFNG ALB
40 chronic inflammatory demyelinating polyradiculoneuropathy 10.5 IFNG ALB
41 neutropenia 10.5
42 spinal cord infarction 10.5 SERPINC1 F2
43 fascioliasis 10.5 IFNG ALB
44 intestinal impaction 10.5 SERPINC1 F2
45 leech infestation 10.5 SERPINC1 F2
46 giant hemangioma 10.5 SERPINC1 F2
47 intracranial embolism 10.5 SERPINC1 F2
48 alpha-2-plasmin inhibitor deficiency 10.5 SERPINC1 F2
49 sagittal sinus thrombosis 10.5 SERPINC1 F2
50 prothrombin deficiency, congenital 10.5 SERPINC1 F2

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Iron Deficiency Anemia Neutropenia
Portal Hypertension Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:



Diseases related to Hypersplenism

Symptoms & Phenotypes for Hypersplenism

MGI Mouse Phenotypes related to Hypersplenism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 ALB CD4 CSF2 EPO F2 FOXP3
2 hematopoietic system MP:0005397 10.06 CD4 CSF2 EPO F2 FOXP3 IFNG
3 cardiovascular system MP:0005385 9.98 CSF2 EPO F2 FOXP3 IFNG PIK3R1
4 immune system MP:0005387 9.97 CD4 CSF2 EPO F2 FOXP3 IFNG
5 integument MP:0010771 9.73 CD4 CSF2 EPO F2 FOXP3 IFNG
6 liver/biliary system MP:0005370 9.63 ALB EPO FOXP3 IFNG PIK3R1 SERPINC1
7 mortality/aging MP:0010768 9.61 ALB CD4 CSF2 EPO F2 FOXP3
8 normal MP:0002873 9.17 ALB CD4 EPO F2 FOXP3 IFNG

Drugs & Therapeutics for Hypersplenism

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
4
tannic acid Approved Phase 4 1401-55-4
5
Nadroparin Approved, Investigational Phase 4
6
Dipyridamole Approved Phase 4 58-32-2 3108
7
Warfarin Approved Phase 4 81-81-2 6691 54678486
8
Dalteparin Approved Phase 4 9005-49-6
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
11
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
12 Immunologic Factors Phase 4
13 Immunosuppressive Agents Phase 4
14 Anti-Bacterial Agents Phase 4
15 Antibiotics, Antitubercular Phase 4
16 Antitubercular Agents Phase 4
17 Anti-Infective Agents Phase 4
18 Calcineurin Inhibitors Phase 4
19 Liver Extracts Phase 4
20 Analgesics Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Fibrinolytic Agents Phase 4
24 Peripheral Nervous System Agents Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Phosphodiesterase Inhibitors Phase 4
27 Heparin, Low-Molecular-Weight Phase 4
28 Platelet Aggregation Inhibitors Phase 4
29 Anticoagulants Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Vasodilator Agents Phase 4
32 Antipyretics Phase 4
33 calcium heparin Phase 4
34 Calcium, Dietary Phase 4
35 Antirheumatic Agents Phase 4
36
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
37
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
38
Valproic acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
39
Melphalan Approved Phase 2 148-82-3 460612 4053
40
Lenalidomide Approved Phase 2 191732-72-6 216326
41
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
42
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
43 Topoisomerase Inhibitors Phase 1, Phase 2
44 Neurotransmitter Agents Phase 1, Phase 2
45 Central Nervous System Depressants Phase 1, Phase 2
46 Tranquilizing Agents Phase 1, Phase 2
47 GABA Agents Phase 1, Phase 2
48 Anticonvulsants Phase 1, Phase 2
49 Antimanic Agents Phase 1, Phase 2
50 Psychotropic Drugs Phase 1, Phase 2

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy Completed NCT00195988 Phase 4 tacrolimus, steroids, mycophenolate mofetil
2 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
3 Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study Unknown status NCT01560845 Phase 2, Phase 3
4 A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients. Unknown status NCT01936064 Phase 1, Phase 2 Placebo + Cyclophosphamide - Epirubicin 6
5 An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01 Completed NCT01488097 Phase 2 sebelipase alfa
6 An Open-Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Participants With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Completed NCT01307098 Phase 1, Phase 2 Sebelipase alfa 0.35 mg/kg;Sebelipase alfa 1 mg/kg;Sebelipase alfa 3 mg/kg
7 Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
8 Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study" Completed NCT00744536 Phase 2 Lenalidomide and melphalan
9 A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE Terminated NCT01539018 Phase 2 Sorafenib;sorafenib plus tegafur-uracil
10 Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy Unknown status NCT03269877
11 Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
12 Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
13 The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy Unknown status NCT02344979
14 A Randomized Controlled Trial of Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection Completed NCT00825669 TACE
15 The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications. Completed NCT00971698
16 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Completed NCT03201367 Rivaroxaban
17 The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension Recruiting NCT02778425
18 Differential Diagnostic of ITP and MDS: a Prospective Study by Next‐Generation Flow Cytometry and Cytomorphological Approaches Recruiting NCT03469661
19 HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803) Recruiting NCT03783065 Propranolol
20 Study of Prognostic Factors of Acute Splenic Sequestration in a Cohort of Sickle Cell Disease (SCD) Children Diagnosed at Birth Active, not recruiting NCT01207037
21 Management of Childhood Pancytopenia in Heamatology Unit in Assiut University Hospital Not yet recruiting NCT03521947
22 Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital Not yet recruiting NCT03533322
23 Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder Terminated NCT00722254

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Genetic Tests for Hypersplenism

Anatomical Context for Hypersplenism

MalaCards organs/tissues related to Hypersplenism:

41
Liver, Spleen, Bone, Bone Marrow, Kidney, T Cells, Myeloid

Publications for Hypersplenism

Articles related to Hypersplenism:

(show top 50) (show all 2051)
# Title Authors PMID Year
1
Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. 9 38
16215425 2005
2
Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. 9 38
12911944 2003
3
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. 9 38
12753144 2003
4
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. 9 38
12399221 2002
5
Role of plasma thrombopoietin level in thrombocytopenia of postoperative biliary atresia patients. 9 38
12149701 2002
6
Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. 9 38
11100362 2000
7
Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. 9 38
11787473 2000
8
Laparoscopic cholecystectomy for cholelithiasis in patients with liver cirrhosis. 9 38
18493357 1995
9
Emergency or urgent splenectomy in children for non-traumatic reasons. 38
31312939 2019
10
Clinical Characteristics and Risk Factors for Sinistral Portal Hypertension Associated with Moderate and Severe Acute Pancreatitis: A Seven-Year Single-Center Retrospective Study. 38
31400275 2019
11
The Effects of Liver Transplantation in Children With Niemann-Pick Disease Type B. 38
30912297 2019
12
Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: A multicentre national study. 38
30928422 2019
13
From sadness to stiffness: the spleen's progress. 38
31152307 2019
14
Graft Hepatic Artery Rupture Due to Carbapenem-Resistant Klebsiella pneumoniae Infection After Liver Transplant. 38
31424357 2019
15
FDG-PET/CT Demonstrates Splenic Angiosarcoma Bone Marrow Metastasis. 38
31306197 2019
16
Comparison of early postoperative results between robot-assisted and laparoscopic splenectomy for non-traumatic splenic diseases rather than portal hypertensive hypersplenism-a meta-analysis. 38
31350089 2019
17
Immunological consequences following splenectomy in patients with liver cirrhosis. 38
31281459 2019
18
Abnormal glucose metabolism in patients with Fontan circulation: Unique characteristics and associations with Fontan pathophysiology. 38
31425899 2019
19
Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients. 38
31273428 2019
20
Recanalization of Chronic Portal Vein Occlusion in Pediatric Liver Transplant Patients. 38
30773434 2019
21
Multiple Giant Splenic Artery Aneurysms with Hypersplenism and Portal Hypertension: A Case Report. 38
31275486 2019
22
Dual-interventional therapy for multiple splenic artery aneurysms in a patient with portal hypertension: A case report. 38
31083153 2019
23
Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: a safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism. 38
31116622 2019
24
Splenic devascularization can replace splenectomy during adult living donor liver transplantation - a historical cohort study. 38
30714245 2019
25
Laparoscopic selective esophagogastric devascularization and splenectomy for patients with cirrhotic portal hypertension. 38
31118982 2019
26
Impact of imbalanced graft-to-spleen volume ratio on outcomes following living donor liver transplantation in an era when simultaneous splenectomy is not typically indicated. 38
30830721 2019
27
Patterns of splenic arterial enhancement on computed tomography are related to changes in portal venous pressure. 38
30334908 2019
28
Splenectomy to Optimize Hemoglobin S Control in Children With Sickle Cell Anemia on Chronic Transfusion Therapy for Stroke Prevention. 38
29668544 2019
29
Massive Splenic Infarction in a Child With Sickle Cell Disease on Chronic Transfusion Therapy. 38
30499910 2019
30
Adverse factors responsible for below-normal platelet count after laparoscopic splenectomy and azygoportal disconnection. 38
30460896 2019
31
Partial splenic embolization with Glubran®2/Lipiodol® mixture for oncological patients with hypersplenism-related thrombocytopenia requiring systemic chemotherapy. 38
31032188 2019
32
Efficacy and safety of partial splenic embolization for hypersplenism in pre- and post-liver transplant patients: A 16-year comparative analysis. 38
30553121 2019
33
Long-Term Results after Diversion Surgery in Extrahepatic Portal Vein Obstruction. 38
30086576 2019
34
Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. 38
29886103 2019
35
Coronary Renal Shunt with Splenectomy (CRSS) for Selective Variceal Decompression. 38
30225560 2019
36
Mutation in ITCH Gene Can Cause Syndromic Multisystem Autoimmune Disease With Acute Liver Failure. 38
30705142 2019
37
Elective Splenectomy Combined with Modified Hassab's or Sugiura Procedure for Portal Hypertension in Decompensated Cirrhosis. 38
31183338 2019
38
Radical surgical treatment of Budd-Chiari syndrome through entire exposure of hepatic inferior vena cava. 38
30341019 2019
39
The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major. 38
30697270 2019
40
[Latent essential thrombocythemia becoming perceptible after splenectomy]. 38
31168000 2019
41
Spontaneous iliopsoas hematoma in a trasfusion dependent β-thalassemia patient with hypersplenism: a case report. 38
30889163 2018
42
Splenectomy for breast carcinoma diffusely metastatic to the spleen presenting as severe transfusion-dependent anaemia and thrombocytopaenia. 38
30567891 2018
43
Isolated Splenic Sarcoidosis With Hypersplenism. 38
30601166 2018
44
Rex Shunt as a Treatment of Type II Abernethy Malformation with Severe Dysplasia of Portal Vein. 38
30081160 2018
45
Laparoscopic splenectomy and azygoportal disconnection combining with pre- and postoperative endoscopic intervention - A sandwich-style sequential therapy for portal hypertensive bleeding: A retrospective cohort study. 38
30289390 2018
46
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. 38
30462857 2018
47
Refractoriness to red blood cell transfusion therapy due to hypersplenism. 38
30260482 2018
48
Long-term Changes in Spleen Volume After Living Donor Liver Transplantation in Pediatric Recipients. 38
30348453 2018
49
Splenic artery embolization with detachable balloons for hypersplenism. 38
30027780 2018
50
Partial splenic embolization in the treatment of prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients. 38
29696427 2018

Variations for Hypersplenism

Expression for Hypersplenism

Search GEO for disease gene expression data for Hypersplenism.

Pathways for Hypersplenism

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.31 THPO PIK3R1 IFNG F2 EPO CSF2
2
Show member pathways
13.21 THPO PIK3R1 IFNG F2 EPO CD4
3
Show member pathways
13.07 THPO PIK3R1 CSF2 CD4 BMP6
4
Show member pathways
13.03 THPO SERPINC1 PIK3R1 F2 CSF2 ALB
5
Show member pathways
12.37 PIK3R1 IFNG F2 CD4
6
Show member pathways
12.3 PIK3R1 IFNG CSF2 CD4
7
Show member pathways
12.12 IFNG F2 ALB
8
Show member pathways
11.92 THPO PIK3R1 IFNG EPO CSF2
9
Show member pathways
11.84 IFNG F2 CSF2
10 11.76 PIK3R1 IFNG EPO
11
Show member pathways
11.73 THPO PIK3R1 IFNG CD4 BMP6
12 11.71 PIK3R1 IFNG CSF2
13 11.68 PIK3R1 IFNG EPO
14
Show member pathways
11.57 IFNG FOXP3 CSF2
15 11.54 IFNG CSF2 CD4
16 11.24 IFNG FOXP3 CD4
17 11.24 THPO EPO CSF2 CD4
18 11.09 THPO IFNG EPO CSF2 CD4
19 11.05 IFNG CD4
20 10.98 IFNG F2
21 10.92 PIK3R1 IFNG
22 10.9 IFNG CSF2 CD4
23 10.8 THPO PIK3R1 CSF2 BMP6

GO Terms for Hypersplenism

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 THPO SERPINC1 IFNG F2 EPO CSF2
2 endoplasmic reticulum lumen GO:0005788 9.46 SERPINC1 F2 CD4 ALB
3 blood microparticle GO:0072562 9.43 SERPINC1 F2 ALB
4 extracellular space GO:0005615 9.23 THPO SERPINC1 IFNG F2 EPO CSF2

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.78 IFNG CSF2 CD4 BMP6
2 cellular protein metabolic process GO:0044267 9.69 SERPINC1 F2 ALB
3 T cell receptor signaling pathway GO:0050852 9.61 PIK3R1 FOXP3 CD4
4 cytokine production GO:0001816 9.49 FOXP3 CD4
5 regulation of regulatory T cell differentiation GO:0045589 9.46 IFNG FOXP3
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 IFNG EPO CSF2
7 regulation of blood coagulation GO:0030193 9.4 SERPINC1 F2
8 negative regulation of interleukin-17 production GO:0032700 9.37 IFNG FOXP3
9 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.32 CSF2 CD4
10 positive regulation of protein phosphorylation GO:0001934 9.26 THPO IFNG F2 CD4
11 positive regulation of interleukin-23 production GO:0032747 9.16 IFNG CSF2
12 positive regulation of cell proliferation GO:0008284 9.1 THPO IFNG F2 EPO CSF2 BMP6

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 THPO F2 CSF2 BMP6
2 cytokine activity GO:0005125 9.02 THPO IFNG EPO CSF2 BMP6

Sources for Hypersplenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....